ALX Oncology Holdings Inc.
ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor inā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.45
Price+2.84%
$0.04
1Y
Price
Market Cap
$78.616m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$108.010m
+19.9%
1y CAGR+1.9%
3y CAGR-10.5%
5y CAGREPS
-$2.03
+21.3%
1y CAGR+9.6%
3y CAGR-4.4%
5y CAGRBook Value
$44.800m
$82.723m
Assets$37.923m
Liabilities$4.348m
DebtDebt to Assets
5.3%
-
Debt to EBITDAFree Cash Flow
-$97.431m
+20.4%
1y CAGR-5.9%
3y CAGR-10.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company